期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

沉默Ku70基因逆转人乳腺癌耐药细胞MCF-7/ADR耐药性 被引量：1

Silence Ku70 gene inverted MCF7/ADR drug resistence to cisplatin
下载PDF
导出
摘要 目的探讨沉默Ku70基因对耐表阿霉素人乳腺癌细胞MCF-7/ADR耐药逆转作用。方法以脂质体包裹的SiRNA-Ku70转染细胞,RT-PCR验证Ku70沉默效率。CCK8试剂盒测定细胞增殖活性,通过Caspase-3分光光度法、AnnexinⅤ-PI染色检测细胞凋亡。结果 SiRNA-Ku70转染组Ku70-mRNA表达明显下降,细胞对表阿霉素的敏感性明显增加,药物半数致死浓度(IC50)由34.38±6.75μg/ml降低为13.06±2.62μg/ml,耐药指数(RI)由8.26减至3.14。以表阿霉素5μg/ml的培养液培养细胞24h,SiRNA-Ku70转染组(12pmol)与阴性对照组及空白对照组相比,caspase-3活性明显增高;凋亡细胞数明显增多。结论 SiRNA-Ku70通过下调Ku70的表达,逆转耐表阿霉素人乳腺癌细胞MCF-7/ADR对表阿霉素的耐药性,降低凋亡域值,从而增强了人乳腺癌细胞对表阿霉素的敏感性。 Objective To explore whether silence Ko70 protein can reverse the resistance of the epirubicin-resistant human breast cancer cell MCF-7/ADR to epirubicin. Methods Transfected SiRNA-Ko70 into MCFT/ADR via liposome, RT-PCR validated the silent efficiency of Ko70. CCK8 kit to determine the cells proliferation activity, Annexin V-PI staining and Caspase-3 kit to detect cells apoptosis. Results SiRNA-Ko70 transfection decreased Ko70-mRNA expression significantly and increased the sensitivity of MCF7/ADR to epirubiein, drug median lethal Concentration （IC50） decreased from 34.38± 6.75 μg/ml to 13.06±2.62 μg/ml,resistantindex （RI） decreased from 8.26 to 3.14. caspase-3 activity and the number of apoptotic cells of SiRNA-Ko70 transfection group （12 pmol） increased significantly compared with the negative control group and blank control group after cultured with 5 μg/ml epirubicin for 24 hours. Conclusion Down regulation of Ko70 could reverse drug re- sistance to epirubicin in human breast cancer cell MCF-7/ADR, reduce apoptosis domain value of MCF-7/ADR and enhance sensitivity of the human breast cancer cell to chemotherapy.
作者 葛亮 佟倜 李欣蓉 崔雪玲 陈芳芳
机构地区 吉林大学第一医院麻醉科 吉林大学第二医院胸外科 吉林大学白求恩医学院 中日联谊医院唐敖庆特聘教授实验室
出处 《中国实验诊断学》 2013年第1期27-30,共4页 Chinese Journal of Laboratory Diagnosis
基金 国家自然科学基金(31101039)
关键词 基因沉默 耐药人乳腺癌细胞 耐药 凋亡 gene siloncing MCF-7/ADR drug resistance apoptosis
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献7

  • 1李亚荣,张捷,王珂,刘冰.沉默Ku70后人耐药肺癌细胞凋亡基因组表达变化及临床意义[J].中国免疫学杂志,2010,26(4):312-314. 被引量：4
  • 2赵博,黎瀚,王知勇.乳腺癌化疗药物耐药性的机制浅析[J].中国当代医药,2011,18(17):9-10. 被引量：4
  • 3VictoriaC. Hodgkinsona, Vijay Agarwala,b,c,Dalia ELFadla,d,et al. Pilot and feasibility study: comparative proteomic analysisby 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as puta-tive biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer[] ] . J Proteomics?2012 ,75(9) :2745.
  • 4GulloC,Au M,Feng G,et al. The biology of Ku and its potentialoncogenic role in cancer[j] . Biochim Biophys Acta, 2006,1765(2):223.
  • 5Tian X,Chen G,Xing H,et al. The relationship between thedown-regulation of DNA-PKcs or Ku70 and the chemosensitiza-tion in human cervical carcinoma cell line HeLa[J] . Oncol Rep,2007,18(4):927.
  • 6HsuJL, Leong PK,Ho YF,et al. Pim-1 knockdown potentiatespaclitaxel-induced apoptosis in human hormone-refractory pros-tate cancers through inhibition of NHEJ DNA repair[J] . CancerLett,2012,319 (2):214.
  • 7BusserB, Sancey L, Josserand V, et al. Amphiregulin promotesresistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation[j] . Mol Ther,2010,18(3) :536.

二级参考文献32

  • 1Guo B Q, Villeneuve D J, Hembruff S L et al. Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure[J]. Breast Cancer Res Treat,2004;85( 1 ) : 31-51.
  • 2Doherty A J, Jackson S P. DNA repair: how Ku makes ends meet[J]. Curr- Biol, 2001 ; 11 (22) : R920-R924.
  • 3Monferran S, Paupert J, Dauvillier Set al. The membrane form of the DNA repair protein Ku interacts at the cell surface with metalloproteinase 9[ J]. EMBO J, 2004; 23 : 3758-3768.
  • 4Walker J R, Corpina R A, Goldberg J. Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair[J]. Nature,2001 ;412:607-614.
  • 5Hengartner M O. The biochemistry of apoptosis[J]. Nature, 2000; 407: 770-776.
  • 6Gama V, Yoshida T, Gomez J A et ol. Involvement of the ttbiquitin pathway in descreasing Ku70 levels inresponse to drug-induced apoptosis[ J ]. Exp Cell Res,2006;312:488-499.
  • 7Cheng E H,Wei M C,Weiler Set al. BCL-2, BCL-X(L) sequester BH.3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis [ J ].Mol. Cell, 2001 ; 8 : 705 -711.
  • 8Guo B, Zhai D, Cabezas E et ol. Humanin peptide suppresses apoptosis by interfering with Bax activation [ J ]. Nature, 2003 ; 423 : 456-461.
  • 9Sawada M, Hayes P, Matsuyama Set al. Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70[J]. Nat Cell Biol, 2003 ; 5 : 352-357.
  • 10Yoshida T, Tomioka I, Nagahara T et al. Bax-inhibiting peptide derived from mouse and rat Ku70[J]. Biochem Biophys Res Commun,2004,321 : 961-966.

共引文献6

同被引文献21

  • 1Sun L,Zhao Y,Gu S, et al. Regulation of the HMOX1 gene bythe transcription factor AP-2S with unique DNA binding site[J],Mol Med Rep,2014,10(1) :423-428.
  • 2Berlato C, Chan KV, Price AM, et al. Alternative TFAP2A iso-forms have distinct activities in breast cancer[J], Breast CancerRes,2011,13(2) :R23.
  • 3Hung SW, Chiu CF, Chen TA, et al. Recombinant viral proteinVP1 suppresses HER-2 expression and migration/metastasis ofbreast cancer[J]. Breast Cancer Res Treat,2012,136 ( 1 ) : 89-105.
  • 4Powe DG, Akhtar G, Habashy HO. et al. Investigating AP-2 andYY1 protein expression as a cause of high HER2 gene transcrip-tion in breast cancers with discordant HER2 gene amplification[J].Breast Cancer Res, 2009,11 (6) .. R90.
  • 5. Breast Cancer Res, 2009 ,11(6) : R90.
  • 6Eletr ZM, Wilkinson KD. Regulation of proteolysis by human deu-biquitinating enzymes[J]. Biochim Biophys Acta, 2014, 1843(1):114-128.
  • 7Rathaus M,Lerrer B,Cohen HY. Deubikuitylation:a novel DUBenzymatic activity for the DNA repair protein, Ku70 [J]. CellCycle,2009,8(12):1843-1852.
  • 8Gong Y, Wang D,Dar JA,et al. Nuclear export signal of andro-gen receptor (NESAR) regulation of androgen receptor level inhuman prostate cell lines via ubiquitination and proteasome-de-pendent degradation [J]. Endocrinology, 2012,153 ( 12) : 5716-5725.
  • 9Wakahashi S,Sudo T,Oka N,et al. VAV1 represses E-cadherinexpression through the transactivation of Snail and Slug:a poten-tial mechanism for aberrant epithelial to mesenchymal transitionin human epithelial ovarian cancer[J]. Transl Res, 2013 , 162(3):181-190.
  • 10Powe DG, Akhtar G,Habashy HO,et al. Investigating AP-2 andYY1 protein expression as a cause of high HER2 gene transcrip-tion in breast cancers with discordant HER2 gene amplification[J]. Breast Cancer Res,2009,11(6) :R9.

引证文献1

二级引证文献2

中国实验诊断学
2013年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部